The Kanakee project builds on the biopharma company’s efforts to increase its U.S. footprint, where it has already spent more than $3 billion, and will focus on producing plasma-derived therapies.
Categories:
Related Post
DOL orders staff not to enforce Biden-era independent contractor rule
The Labor Department is still considering whether to rescind the rule, which faces ongoing litigation,…
Whiting-Turner to build new HQ in Baltimore
The builder and Goucher College will use the new facility to introduce young people to…
Gilbane launches procurement division
The builder has hired former Turner Construction executive Suzanne Bennett to lead its new subsidiary…